Stevanato Group S.p.A.
HealthcareNYSE:STVN · New York Stock Exchange
-$0.21 today
Vol 0.49M · Avg 0.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
9.0%
avg 12.6%
ROIC
6.4%
avg 7.9%
ROA
5.3%
avg 6.0%
Analysis
ROE is currently the strongest return metric at 9.0% versus its period average of 12.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Franco Stevanato | Chief Executive Officer & Executive Chairman | — | — | 53 | $0.00 | <0.01% |
Marco Dal Lago | Chief Financial Officer | — | — | 53 | $75,000.00 | 0.03% |
Mauro Stocchi | Chief Business Officer | — | — | 59 | $404,942.00 | 0.15% |
Michele Monico | President of DDS & IVD Business Unit | — | — | — | — | — |
Raffaele Pace | President of Engineering Business Unit | — | — | — | — | — |
Carla Costa | Chief Human Resources Officer | — | — | — | — | — |
Lisa Miles | Chief Communications & Investor Relations Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +25.2% | +12.6% (7yr)1 analysts |
| Revenue | N/A | N/A | +17.9% | +7.4% (7yr)2 analysts |
| Net Income | N/A | N/A | +22.9% | +13.1% (7yr)2 analysts |
| EBIT | N/A | N/A | +24.9% | +6.8% (7yr)2 analysts |
Analysis
Recent growth has been strongest in EPS at +25.2% over three years. Forward estimates point to Net Income at +13.1% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.13B
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
$12.26B
Masimo Corporation
NASDAQ:MASI
$9.42B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Avantor, Inc.
NYSE:AVTR
$6.41B
Teleflex Incorporated
NYSE:TFX
$5.78B
Chemed Corporation
NYSE:CHE
$5.57B
Bausch + Lomb Corporation
NYSE:BLCO
$5.38B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.97B
Who manages STVN?
Stevanato Group S.p.A. (STVN) lists 7 active executives. The top listed executive is Franco Stevanato, Chief Executive Officer & Executive Chairman.
Are STVN insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.